McKinsey has turned the corner on the Asia-centric model of globalization. It’s a “now-or-never” moment for US manufacturing. Here’s where CPA sees eye-to-eye.
From retail investors in China ETFs, to Wall Street’s largest investment firms, China’s new technologies can always count on tens of millions of dollars of inflows from Americans. What do we get in return?
How do we bring back generic drug manufacturing to the United States in order to be less reliant on India, China? A National Academies of Science conference brings in some experts to try and answer that, including the chair of CPA Healthcare Committee.
The trend continues. A Chinese couple indicted over biotech trade secret’s lifted from Ohio research hospital.
A recent Senate Finance Committee hearing on the China threat bodes well for ongoing bipartisan support for American manufacturing. There are right ways and wrong ways to go about this. The wrong way: waiting for allies. The right way: revamping tariff laws that makes reindustrialization profitable.
Striking all the right chords and buzzwords, China leader Xi Jinping says what the world needs now is love sweet love. Who’s buying?
A look at the destructive pricing pressures on American cattle ranchers, and the minority and tribal groups that depend on them. Are we outsourcing cattle ranching in the name of climate change?
For Katherine Tai and the Biden administration, environmentalism is going to be the core of trade policy. How does that square with heavy polluters like India and China?
Recent shortages an example of America’s over-bearing dependence on Chinese supply chains. The time is now to take action to reverses this decades-long headwind to U.S. manufacturing and its labor force.
A Senate hearing today looked back at our early response to the pandemic. A year later, what went right, what went wrong, and how to re-shore pharma now.